Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) were developed to target the EGFR T790M resistance mutation in non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs. To investigate the efficacy of afatinib treatment...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Sci Rep
Hauptverfasser: Ishii, Hidenobu, Azuma, Koichi, Sakai, Kazuko, Naito, Yoshiko, Matsuo, Norikazu, Tokito, Takaaki, Yamada, Kazuhiko, Hoshino, Tomoaki, Nishio, Kazuto
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6971280/
https://ncbi.nlm.nih.gov/pubmed/31959859
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-57624-4
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge